- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05738733
A Clinical Efficacy Study of MsChief Personal Lubricant in Healthy Female Subjects
A Proof of Science, In-Use Tolerance, Safety, and Efficacy Clinical Study of MsChief Personal Lubricant in Healthy Female Subjects
A Proof of Science, Open-Label, Single Centre, Four-Arm, In-Use Tolerance, Safety, and Efficacy Clinical Study of MsChief Personal Lubricant in Healthy Female Subjects.
30 subjects/product (33 subjects' enrolment/treatment) healthy non-pregnant/non-lactating females with an age of 18 - 65 years old.
A total of up to 132 subjects (33 subjects/product) will be enrolled to get 120 completed subjects (30 subjects/product) in the study.
Study Overview
Status
Conditions
Detailed Description
A sufficient number of healthy female subjects with an age group of 18 - 65 years old with a Nugent score ≤3 will be recruited/enrolled.
The potential subjects will be screened as per the inclusion & exclusion criteria only after obtaining written informed consent from the subjects. The subjects will be instructed to visit the facility as per the below visits
- Visit 01 (Within 07 Days): Screening, Baseline evaluations
- Visit 02 (Day 01): Enrolment & Test Products usage phase start
- Visit 03 (Day 16): Test Products usage ends, End of the study Subjects will be pre-screened by the screening department of NovoBliss Research. Subjects will be telephonically contacted by recruiting department prior to the enrolment visit. Subjects will be instructed during screening (prior to enrolment) not to use any other product for intimate washes, lubricant, or any other product during the study.
Assessment of efficacy parameters will be done before test products usage on Day 1 and will be compared with after test products usage during Day 16 as listed below.
Gynaecological Assessments
- Local irritation, pruritus, erythema, edema
- Moisturizing effect - moisture, dryness, flaking, epithelial mucosa
- Quality and odour of vaginal discharge
- Vaginal pH measure using pH paper
- Clinical symptoms associated with infections
- Verbal rating scale (0-4 score)- Vaginal itching
Subjective Self-assessments
- Perceived irritations - Burning, Itching, Stinging, Discomfort
- Sexual activity (where appropriate)
- VAS Scoring for Vaginal itchiness
- Quality of life assessment
- Microbiological Assessments • Nugents scoring
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Gujarat
-
Gandhinagar, Gujarat, India, 382421
- Krisha Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age: 18 to 65 years (both inclusive) at the time of consent.
Sex: Healthy non-pregnant/non-lactating females
- Females of fertile reproductive age with a propensity to vulvo-vaginal infection (18 years to 40 years)
- Females in the pre-menopausal age group (41 years to 48 years)
- Females in the post-menopausal age group (49 years to 65 years)
- The subject is with Nugent score ≤3.
- The subject with an active sex life of at least 01 sexual intercourse in a week
- The subject of childbearing potential must have a reported negative pregnancy during screening and the end of the study.
- The subject without a history of sensitivity to similar products/formulations
- The subject is willing to give written informed consent and is willing to follow the study procedures.
- The subject is willing to abide by the study protocol and study restrictions including abstinence from the use of any other product besides the test product for intimate wash, lubricant or any other products during the study.
- The subject is a personal lubricant user and agrees to replace her usual personal lubricant with the test product.
- The subject of childbearing potential who is willing to use a highly effective method of contraception throughout the clinical investigation.
- The subject is of childbearing potential, is practising and agrees to maintain an established method of birth control (IUD, hormonal implant device/injection, regular use of birth control pills or patch, diaphragm, condoms, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation.
- If currently using hormonal contraception, has been using this form of contraception for at least 6 months and agrees to continue using the same contraception for the duration of the study.
- The subject who agrees to have a gynaecological pelvic examination to ensure no significant disease findings and have intact skin and mucous in the test region assessed by the gynaecologist at all the relevant time points
Exclusion Criteria:
- The subject used other intra-vaginal gel moisturizers during the study.
- The subject with Nugent score >3.
- The subject who is diagnosed with cancer
- The subject using hormone replacement therapy for the last 3 months
- The subject has a history or visible evidence of chronic skin disease or regional infections, genital herpes, vaginal infections or urinary tract infections.
- Pregnant or lactating, women who are likely to become pregnant.
- The subject exhibits or reports gynecologic abnormalities or has had vaginitis within 60 days prior to study initiation.
- Personal history of allergy and hypersensitivity to any product of feminine hygiene, severe systemic complications of viral infections, severe systemic illness like cardiovascular disorders, neurological disorders, renal disorders, and autoimmune disorders.
- The subject with any form of chronic infection/ allergy/ disease which may influence the study result
- The subject with bacterial vaginosis/candidiasis/mycotic infections
- The subject participated in clinical studies or had received any investigational agent in the previous 30 days.
- The subject is not willing to sign an informed consent form.
- The subject is an employee at the site or a partner or first-degree relative of the Investigator.
- The subject fails to satisfy the Investigator of fitness to participate for any other reason.
- The subject has had previous episodes of vaginal bleeding of unknown origin within the last 6 months of the screening visit.
- The subject showed vaginal prolapse and/or other medical conditions that could interfere with the study's conduct and participation.
- The subject who has used any kind of systemic and/or local hormonal products for vaginal dryness or any other vaginal condition in the 3 months prior to screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MsChief Classic Natural Lubricant
MsChief Classic natural lubricant contains aqua, propylene glycol, hydroxyethyl cellulose, ethyl menthane carboxamide and methyl diisopropyl propionamide, aloe barbadensis leaf juice, benzoic acid, hippophae Rhamnoides extract, tocophersolan, sodium hydroxide.
MsChief Classic natural lubricant is a special moisturizer with aloe vera, vitamin E and sea buckthorn.
It not only conditions but also moisturises the skin.
This lubricant is water-based is free of sugar or saccharine.
This product does not contain paraben or glycerine.
This product has a unique formulation pH ideal for intimate area.
|
Apply the desire amount of lubricant on the body to make it more sensitive.
|
Experimental: MsChief Ylang Ylang Natural Lubricant
MsChief Ylang Ylang natural lubricant contains aqua, propylene glycol, flavour, hydroxyethyl cellulose, ethyl menthane carboxamide and methyl diisopropyl propionamide, aloe barbadensis leaf juice, benzoic acid, hippophae Rhamnoides extract, tocophersolan, sodium hydroxide.
MsChief Ylang Ylang natural lubricant is a special moisturizer with aloe vera, vitamin E and sea buckthorn It not only conditions but also moisturise the skin.
This lubricant is water-based contain natural flavour and free of sugar or saccharine.
This product does not contain paraben or glycerine.
This product has a unique formulation pH ideal for intimate area.
|
Apply the desire amount of lubricant on the body to make it more sensitive.
|
Experimental: MsChief Vanilla & Citrus Natural Lubricant
MsChief vanilla and citrus natural lubricant contain aqua, propylene glycol, flavour, hydroxyethyl cellulose, ethyl menthane carboxamide and methyl diisopropyl propionamide, aloe barbadensis leaf juice, benzoic acid, hippophae Rhamnoides extract, tocophersolan, sodium hydroxide.
MsChief vanilla and citrus natural lubricant is a special moisturizer with Aloe vera, vitamin E and sea buckthorn.
It not only conditions but also moisturise the skin.
This lubricant is water based contain natural flavour and free of sugar or saccharine.
This product does not contain paraben or glycerine.
This product has a unique formulation pH ideal for intimate area.
|
Apply the desire amount of lubricant on the body to make it more sensitive.
|
Experimental: MsChief Tea & Peach Natural Lubricant
MsChief tea & peach natural lubricant contains aqua, propylene glycol, flavour, hydroxyethyl cellulose, ethyl menthane carboxamide and methyl diisopropyl propionamide, aloe barbadensis leaf juice, benzoic acid, hippophae Rhamnoides extract, tocophersolan, sodium hydroxide.
MsChief tea & peach natural lubricant is a special moisturizer with Aloe vera, vitamin E and sea buckthorn.
It not only conditions but also moisturises the skin.
This lubricant is water-based contains natural flavour and is free of sugar or saccharine.
This product does not contain paraben or glycerine.
This product has a unique formulation pH ideal for intimate area.
|
Apply the desire amount of lubricant on the body to make it more sensitive.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in vaginal local irritation
Time Frame: From baseline i.e. Day 01 (before application) to Day 16 post usage
|
To assess the test product(s) effectiveness in terms of change in vaginal local irritation by the Gynecologist using 4-point scale[0=absent, 1=mild, 2=moderate, 3=severe]..
|
From baseline i.e. Day 01 (before application) to Day 16 post usage
|
Change in vaginal moisturizing effects
Time Frame: From baseline i.e. Day 01 (before application) to Day 16 post usage
|
To assess the test product(s) effectiveness in terms of change in vaginal moisturizing effects as evaluated by the Gynecologist using Modified Schemer Test
|
From baseline i.e. Day 01 (before application) to Day 16 post usage
|
Change in sexual intimacy
Time Frame: From baseline i.e. Day 01 (before application) to Day 16 post usage
|
To assess the test product(s) effectiveness in terms of change in sexual intimacy using female sexual function index self-reported scale score [score of zero indicates that the subject reported having no sexual activity during the past 15 days].
|
From baseline i.e. Day 01 (before application) to Day 16 post usage
|
Change in VAS score for vaginal itching
Time Frame: From baseline i.e. Day 01 (before application) to Day 16 post usage
|
To assess the test product(s) effectiveness in terms of change in Visual Analog Score score for vaginal itching as evaluated by the Gynecologist [ 0 points - No itchiness, greater than or equal to 9 points: Very severe Itchiness
|
From baseline i.e. Day 01 (before application) to Day 16 post usage
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in quality and odor of vaginal discharge
Time Frame: From baseline i.e. Day 01 (before application) to Day 16 post usage
|
To assess the test product(s) effectiveness in terms of change in quality and odor of vaginal discharge as evaluated by the Gynecologist using vaginal odour score [0=absent, 1=mild, 2=moderate, 3=intense, 4=very intense].
|
From baseline i.e. Day 01 (before application) to Day 16 post usage
|
Change in vaginal pH
Time Frame: From baseline i.e. Day 01 (before application) to Day 16 post usage
|
To assess the test product(s) effectiveness in terms of change in vaginal pH as evaluated by the Gynecologist using pH paper
|
From baseline i.e. Day 01 (before application) to Day 16 post usage
|
Change in clinical symptoms associated with infection
Time Frame: From baseline i.e. Day 01 (before application) to Day 16 post usage
|
To assess the test product(s) effectiveness in terms of change in clinical symptoms associated with infection i.e. redness, itching, burning sensation, swelling of vaginal vulva, vaginal rash as evaluated by the Gynecologist using 4-point scale [0=absent, 1=mild, 2=moderate, 3=severe].
|
From baseline i.e. Day 01 (before application) to Day 16 post usage
|
Change in Nugents score
Time Frame: From baseline i.e. Day 01 (before application) to Day 16 post usage
|
To assess the test product(s) effectiveness for change in Nugents score for microbial assessment [0-3: Normal, 4-6: Intermediate bacterial count, 7-10: Bacterial vaginosis].
|
From baseline i.e. Day 01 (before application) to Day 16 post usage
|
Product perception and consumer feedback
Time Frame: From baseline i.e. Day 01 (before application) to Day 16 post usage
|
To assess the effect of the test product(s) assessed in terms of product perception and consumer feedback using 9 point hedonic scoring scale
|
From baseline i.e. Day 01 (before application) to Day 16 post usage
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Dr Nayan K Patel, MBBS, Medical Director
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- NB230002-TT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Females
-
PfizerCompleted
-
University of North Carolina, Chapel HillCompletedHealthy Adult FemalesUnited States
-
Hadassah Medical OrganizationActive, not recruitingPregnant, Healthy Females | Healthy Male NewbornsIsrael
-
University of North Carolina, Chapel HillGlaxoSmithKlineCompletedHealthy Adult FemalesUnited States
-
PfizerCompletedHealthy FemalesUnited States
-
Texas Tech UniversityMetabolic Technologies Inc.; Dymatize Enterprises, LLCCompletedHealthy Active FemalesUnited States
-
The Hospital for Sick ChildrenCanadian Institutes of Health Research (CIHR)CompletedHealthy Females | Protein RequirementCanada
-
Universiti Tunku Abdul RahmanCompletedNo Condition, Healthy FemalesMalaysia
-
Organon and CoCompleted
-
University of North Carolina, Chapel HillCompletedHealthy Adult FemalesUnited States
Clinical Trials on MsChief Classic Natural Lubricant
-
Chulalongkorn UniversityUnknown